

Investment case for adult genomic screening for disease prevention

OUR CURRENT ASK OF GOVERNMENT



\$50 million

Investment
required over
5 years



100,000

Adults
tested



Three

Medically actionable
conditions
(cancer and heart
disease)



~2000

High-risk
individuals
identified and
provided risk
management



Models of care

Evaluated to
inform scale-up

ECONOMIC MODELLING SUPPORTING THE PROPOSAL



8.3 million

Whole population
of eligible adults
aged 18–40



**\$832
million**

Cost of
screening
for 50% uptake
at \$200/test



**\$282
million**

Downstream
healthcare
costs



~\$3 billion

Productivity
gain



3912

Prevented
cancers
and heart
disease



31,094

Quality-adjusted
life years
(cost per QALY):
\$23,963

REFERENCES

DNA Screen pilot study outcomes



Lacaze, Tiller *et al.*,
Nature Health, **2026**,
DOI: 10.1016/j.eclinm.2023.102297

Cost-effectiveness modelling



Lacaze *et al.*,
eClinicalMedicine, **2023**,
DOI: 10.1016/j.eclinm.2023.102297




Dr Jane Tiller
0413 741 187
Jane.Tiller@monash.edu

CONTACT

Prof. Paul Lacaze
0409 416 931
Paul.Lacaze@monash.edu

Distribution of 10,263 enrolled DNA Screen participants (unique postcodes)



Distribution of 202 high-risk participants

